Effect of Angiotensin II Receptor Blockers (ARB) on Left Ventricular Reverse Remodelling After Aortic Valve Replacement in Severe Valvular Aortic Stenosis
Recruitment status was Active, not recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The consequence of aortic valve stenosis (AVS) is increased pressure load on the left ventricle which causes left ventricular (LV) hypertrophy, and myocardial stretch will cause activation of cardiac peptides and activation of the renin angiotensin aldosterone system (RAAS). The consequence of LV hypertrophy is increased chamber-stiffness and delayed active LV relaxation which initially will cause diastolic and later systolic dysfunction. In heart failure (HF) and ischemic heart disease the degree of diastolic dysfunction has been demonstrated to correlate with functional class, neurohormonal activation and prognosis which also recently have been suggested for AVS.
With longstanding elevated filling pressures the left atrium (LA) will dilate. Only limited data are available on the degree and importance of LA dilatation in AVS.
When apparent, symptoms of HF in AVS are associated with high mortality rates. If LV systolic dysfunction also is present prognosis will deteriorate further. In these cases aorta valve replacement (AVR) is recommended. AVR will normalize pressure overload and thereby decreases LV hypertrophy. Previously it was believed that in time LV hypertrophy regressed towards normal and even normalized. Recent studies however have demonstrated that LV hypertrophy regression mainly happens during the first year after AVR, and little subsequent changes are seen during the remaining 10 years. Furthermore, patients that experience most regression of hypertrophy have more favourable outcome and better functional class than patients with less regression of hypertrophy. Thus absence of reverse remodelling is associated with poor outcome after AVR. Importantly the regression of LV hypertrophy is closely paralleled by decreasing RAAS hyperactivity.
RAAS hyperactivity may be attenuated pharmacologically with angiotensin II receptor blockers (ARB) which in systemic hypertension with LV hypertrophy has been associated with reverse remodelling.
The hypothesis is that in patients undergoing AVR for symptomatic AVS, 12 months post operative blockade of the angiotensin II receptor will accelerate LV and LA reverse remodelling, reduce filling pressures and suppress neurohormonal activation compared with conventional therapy. This will lead to improved exercise tolerance and due to improved left atrial function reducing the risk of atrial arrythmias.
| Condition | Intervention | Phase |
|---|---|---|
|
Aortic Valve Stenosis Left Ventricular Hypertrophy Atrial Fibrillation |
Drug: Candesartan |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Factorial Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Left Ventricular Reverse Remodelling After Aortic Valve Replacement in Severe Valvular Aortic Stenosis - Effect of Blockade of the Angiotensin-II Receptor |
- LV mass index
- LA volume index
- Plasma nt-pro BNP concentration
- Diastolic E/e' ratio
- Overall LV function assessed by the Doppler echocardiographic Tei Index
- Regional LV function assessed with tissue Doppler imaging
- LV end systolic and end diastolic volume index
- Atrial arrhythmias assessed with 48h Holter after 12 months
- Exercise capacity after 12 months
- Serial changes in LV diastolic, overall LV function and regional LV systolic function
- Assess serial changes in plasma nt-pro BNP, ANP, and renin
| Estimated Enrollment: | 140 |
| Study Start Date: | February 2006 |
| Estimated Study Completion Date: | June 2009 |
| Estimated Primary Completion Date: | January 2009 (Final data collection date for primary outcome measure) |
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Symptomatic severe AVS referred for valve replacement (mechanic prosthesis or bioprosthesis) at Odense University Hospital
- Signed informed consent
Exclusion Criteria:
- Severe renal failure (s-creatinine >300 mmole/l)
- Moderate or severe hepatic failure
- Moderate or severe LV systolic dysfunction (LVEF<40%)
- Patients already treated with ACE-I or ARB
- Known intolerance for ARB
- Unwilling to participate in the study
- Poor echocardiographic window
- Pregnant women
Contacts and Locations| Denmark | |
| Cardiology Department, Odense University hospital | |
| Odense, Fyn, Denmark, 5000 | |
| Study Director: | Torben Haghfelt, Md, DMSc | Kardiologisk forskningsenhed, OUH |
| Principal Investigator: | Jordi S Dahl, MD, MMSci | Kardiologisk forskningsenhed, OUH |
| Study Chair: | Henrik Nissen, MD, PhD | Kardiologisk forskningsenhed, OUH |
| Study Chair: | Jacob E Moller, Md, Ph.D | Kardiologisk forskningsenhed, OUH |
| Study Chair: | Lars Videbæk, MD, Ph.d | Kardiologisk forskningsenhed, OUH |
| Study Chair: | Lars I Andersen, MD, DMSc | Department of thoracic surgery, OUH |
More Information
Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| ClinicalTrials.gov Identifier: | NCT00294775 History of Changes |
| Other Study ID Numbers: | EudraCT number 2005-001930-34 |
| Study First Received: | February 21, 2006 |
| Last Updated: | June 26, 2009 |
| Health Authority: | Denmark: Danish Medicines Agency Denmark: The Regional Committee on Biomedical Research Ethics Denmark: Danish Dataprotection Agency |
Keywords provided by Odense University Hospital:
|
diastolic dysfunction Reverse Remodelling |
Additional relevant MeSH terms:
|
Aortic Valve Stenosis Atrial Fibrillation Constriction, Pathologic Hypertrophy Hypertrophy, Left Ventricular Heart Valve Diseases Heart Diseases Cardiovascular Diseases Ventricular Outflow Obstruction Arrhythmias, Cardiac Pathologic Processes Pathological Conditions, Anatomical |
Cardiomegaly Angiotensin II Candesartan Candesartan cilexetil Angiotensin Receptor Antagonists Vasoconstrictor Agents Cardiovascular Agents Therapeutic Uses Pharmacologic Actions Antihypertensive Agents Angiotensin II Type 1 Receptor Blockers Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on May 23, 2013